Advertisement

Effect of Peptides on Brain Monoamines and on Gross Behaviour

  • Arvid Carlsson
  • J. A. Garcia-Sevilla
  • Tor Magnusson
Part of the Published Nobel Symposia book series (NOFS, volume 42)

Abstract

The discovery of a large number of endogenous peptides with possible neurotransmitter functions in various brain regions (see Hökfelt, This Symposium) raises the question as to the role of these neuropeptides in brain physiology as well as in neuropsychiatric disorders. The neuropeptides do not readily pass through the blood-brain barrier and thus it is doubtful to what extent systemic administration of the neuropeptides will help to elucidate their functions in the CNS. In the future we may expect that synthetic neuropeptide analogues capable of penetrating this barrier will become available. In fact, such development is already underway. Meanwhile we must resort to local application procedures. In the present investigation we have studied the effects of intracerebroventricular injections of several neuropeptides as well as of synthetic analogues. In view of the apparently close relationship between the neuropeptides and the monoamines (see Hökfelt, this Symposium) we have studied the effects of the neuropeptides on the synthesis and utilization of the brain monoamines. In addition, observations on gross behaviour and locomotor activity were recorded.

Keywords

Corpus Striatum Increase Locomotor Activity Brain Monoamine Limbic Forebrain Dopa Formation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Andén, N.-E., K. Fuxe and T. Hökfelt. Eur. J. Pharmac. 1:226, 1967.CrossRefGoogle Scholar
  2. 2.
    Carlsson, A. In: M.A. Lipton, A. DiMascio and K.F. Killam (Eds.), Psychopharmacology: A Generation of Progress. New York: Raven Press. 1978, p. 1057.Google Scholar
  3. 3.
    Carlsson A., J.N. Davis., W. Kehr, M. Lindqvist and C.V. Atack. Naunyn-Schmiedeberg’s Arch. Pharmac. 275: 153, 1972.CrossRefGoogle Scholar
  4. 4.
    Carlsson A., T. Magnusson, G.H. Fisher, D. Chang and K. Folkers. In: U.S. von Euler and B. Pernov (Eds.), Substance P. New York: Raven Press, 1977. p. 201.Google Scholar
  5. 5.
    Garcia-Sevilla, J.A., L. Ahtee, T. Magnusson and A. Carlsson. J. Pharm. Pharmac. (in press).Google Scholar
  6. 6.
    Garcia-Sevilla, J.A., T. Magnusson and A. Carlsson. Brain Research (in press).Google Scholar
  7. 7.
    Hökfelt, T., L.G. Elfvin. R. Elde, M. Schultzberg, M. Goldstein and R. Luft. Pro. Natl. Acad. Sci. USA 74: 3587, 1977.CrossRefGoogle Scholar
  8. 8.
    Magnusson, T., A. Carlsson, G.H. Fisher, D. Chang and K. Folkers. J. Neural Trans. 38: 89, 1976.CrossRefGoogle Scholar
  9. 9.
    Pert, C.B., A. Pert, J.-K. Chang and B.T.W. Fong. Science 194: 330, 1976.PubMedCrossRefGoogle Scholar
  10. 10.
    Roemer, D., H.H. Buescher, R.C. Hill, J. Pless, W. Bauer, F. Cardinauxt A. Closse, D. Hauser and R. Huguenin. Nature 268s 547, 1977.CrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1979

Authors and Affiliations

  • Arvid Carlsson
    • 1
  • J. A. Garcia-Sevilla
    • 1
  • Tor Magnusson
    • 1
  1. 1.Department of PharmacologyUniversity of GöteborgGöteborgSweden

Personalised recommendations